V gamma 9 V delta 2 T-cell receptor and Low affinity immunoglobulin gamma Fc receptor III-A (CD16a) (Vγ9Vδ2 TCR/CD16)

γδ2 T-cell surface anchoring receptors, primarily the Vγ9Vδ2 T-cell receptor (TCR) and CD16 (FcγRIIIa), serve as critical docking sites for the attachment of therapeutic antibodies in Antibody-Cell Conjugation (ACC) technology. This innovative platform, developed by companies like Acepodia, utilizes a DNA-based or chemical linker to conjugate antibodies directly to these receptors on the surface of γδ2 T cells without the need for genetic engineering. The Vγ9Vδ2 TCR is the dominant TCR subset in human peripheral blood and naturally recognizes phosphoantigens, while CD16 is a potent mediator of antibody-dependent cellular cytotoxicity (ADCC). By anchoring antibodies to these receptors, the γδ2 T cells are effectively 'armored' and redirected to target specific tumor-associated antigens, such as CD20 in lymphomas or EGFR in solid tumors. This approach enhances the natural anti-tumor potency of γδ T cells and provides a versatile, off-the-shelf alternative to traditional CAR-T cell therapies.

Other names

γδ2 T-cell surface anchoring receptorsCD16FcγRIIIaVγ9Vδ2 TCRAntibody-Cell Conjugation (ACC) anchorsSurface anchoring receptors for ACC

Antibody-Cell Conjugation (ACC) technology involves the chemical or enzymatic linkage of therapeutic antibodies to surface anchoring receptors, primarily CD16 and the Vγ9Vδ2 TCR, on γδ2 T cells. This conjugation redirects the immune cells to specific tumor antigens (e.g., CD20 or EGFR) and triggers T-cell activation and cytotoxicity upon binding to the target tumor cells.